These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

887 related items for PubMed ID: 20837949

  • 21. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, Yokosuka O, Takagi T, Kumagai K.
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH.
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [Abstract] [Full Text] [Related]

  • 24. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
    Feeney SA, McCaughey C, Watt AP, Agnaf MR, McDougall N, Wend UC, Gerlich WH, Coyle PV.
    J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
    [Abstract] [Full Text] [Related]

  • 25. Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy.
    Cheung WI, Lin SY, Leung VK, Fung KS, Lam YK, Lo FH, Chau TN.
    Hong Kong Med J; 2011 Oct; 17(5):376-80. PubMed ID: 21979474
    [Abstract] [Full Text] [Related]

  • 26. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S.
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [Abstract] [Full Text] [Related]

  • 27. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B, Samuel D.
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [Abstract] [Full Text] [Related]

  • 28. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
    Ishihara T, Kanagawa M, Koyama J, Hasegawa K, Suzuki T, Hirayama Y, Terui T.
    Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
    [Abstract] [Full Text] [Related]

  • 29. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
    Muñoz Bertrán E, Pérez Ceballos E, Gómez Espín R, Ortega González I.
    Gastroenterol Hepatol; 2010 May; 33(5):377-81. PubMed ID: 20363054
    [Abstract] [Full Text] [Related]

  • 30. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment.
    Kim MG, Park SY, Kim EJ, Kim YM, Kim HY, Lee YK, Zang DY, Kim HJ.
    Acta Haematol; 2011 Oct; 125(3):121-4. PubMed ID: 21150178
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
    Koo YX, Tan DS, Tan BH, Quek R, Tao M, Lim ST.
    J Clin Oncol; 2009 May 20; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
    [No Abstract] [Full Text] [Related]

  • 37. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N.
    Ann Hematol; 2004 Jan 20; 83(1):58-60. PubMed ID: 14513286
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.